Bioavailability and Food Effect of Ubrogepant ODT in Healthy Volunteers

Phase 1, randomised, open-label trial of ubrogepant in migraine (4 arms), sponsored by AbbVie Inc. Primary endpoints: Number of Participants Experiencing Adverse Events at 33 days, Area under the plasma concentration-time curve from time 0 until the last measurable concentration at 3 days and 8 more. Started Jul 2026; status: active, not recruiting.